PSA bouncing after external beam radiation for prostate cancer with or without hormonal treatment

European Urology

Volumn 43, Issue 5, 2003, Pages 473-477

  Sengoz, Meric ^a   Abacioglu, Ufuk ^a   Cetin, Ilknur ^a   Turkeri, Levent ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Biochemical failure; Prostate cancer; Prostate specific antigen; PSA bounce; Radiotherapy

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOSE RESPONSE; FOLLOW UP; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION DOSE; RADIATION DOSE FRACTIONATION; TREATMENT OUTCOME;

EID: 0037967352     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(03)00138-6     Document Type: Article

References (14)

1. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff R, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
2. Pilepich MV, Krall JM, Al-Sarraf M, John MJ, Doggett RLS, Sause WL, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995;45:616-23.
3. Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49:937-46.
4. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035-41.
5. Critz FA, Williams WH, Benton JB, Levinson AK, Holladay CT, Holladay DA. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol 2000;163:1085-9.
6. 103Pd brachytherapy for localized prostate cancer. Semin Urol Oncol 2000;18:160-5.
7. Das P, Chen MH, Valentine K, Lopes L, Cormack RA, Renshaw AA, et al. Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce. Int J Radiat Oncol Biol Phys 2002;54:698-702.
8. Smathers S, Wallner K, Sprouse J, True L. Temporary PSA rises and repeat prostate biopsies after brachytherapy. Int J Radiat Oncol Biol Phys 2001;50:1207-11.
9. Patel C, Elshaikh MA, Angermeier K, Ulchaker J, Klein EA, Chidel MA, et al. Erratic PSA behavior (PSA bounce) following permanent 1-125 implantation of the prostate. Int J Radiat Oncol Biol Phys 2001;51(Suppl 1):277 [Abstract].
10. Rosser CJ, Kuban DA, Levy LB, Chichakli R, Pollack A, Lee AK, et al. The prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J Urol 2002;168:2001-5.
11. Hanlon AL, Pinover WH, Horwitz EM, Hanks GE. Patterns and fate of PSA bouncing following 3D-CRT. Int J Radiat Oncol Biol Phys 2001;50:845-9.
12. Fleming ID, Coper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, et al., editors. AJCC cancer staging manual. 5th edition. Philadelphia (PA): Lippincott-Raven; 1997. p. 219-24.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:447-57.
14. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.